Article Information
History
- July 19, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- TA Fox1,2,
- AA Kirkwood3,
- L Enfield2,
- M O’Reilly2,
- S Arulogun2,
- S D’Sa2,
- J O’Nions2,
- J Kavi5,
- E Vitsaras4,
- W Townsend2,
- SO Burns1,5,
- SH Gohil2,
- K Cwynarski2,
- KJ Thomson2,
- M Noursadeghi6,7,
- RS Heyderman6,7,
- T Rampling7,
- KM Ardeshna2,
- LE McCoy1,6,* and
- EC Morris1,2,*,#
- 1UCL Institute of Immunity & Transplantation, University College London, London, UK
- 2Department of Clinical Haematology, University College London Hospitals NHS Foundation Trust, London, UK
- 3CR UK & UCL Cancer Trials Centre, UCL Cancer Institute, UCL, London, UK
- 4Health Services Laboratories, London, UK
- 5Immunology, Royal Free London Hospitals NHS Foundation Trust, London, UK
- 6Research Department of Infection, University College London, London, UK
- 7Department of Infectious Disease, University College London Hospitals NHS Foundation Trust, London, UK
- ↵#Corresponding Author:
Professor Emma C Morris, Email: e.morris{at}ucl.ac.uk
Posted July 19, 2021.
Low seropositivity and sub-optimal neutralisation rates in patients fully vaccinated against COVID-19 with B cell malignancies
